查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698463

人类微生物组市场：2025-2030 年预测

Human Microbiome Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

人类微生物组市场预计将从 2025 年的 941,215,000 美元增长到 2030 年的 2,383,317,000 美元，复合年增长率为 20.42%。

推动全球人类微生物组市场成长的关键因素是文明病和性行为感染的增加、全球人口生活方式的改变、老年人口的增加及其在医疗保健中的应用。此外，生物医学科学的技术进步以及技术和产品领域的研究投资不断增加也对市场成长产生了积极影响。然而，对益生元和益生菌的用途和益处缺乏认识以及政府对其使用的监管是市场参与者面临的主要挑战。

市场趋势：

  • 人类微生物组市场深入分析：全球人类微生物组市场报告对产业格局进行了全面的研究，提供了由数据驱动的预测和深入分析支援的策略和执行层面的见解。
  • 为决策者提供可行的见解：该报告定期更新，为决策者提供有关市场趋势、新兴机会和竞争动态的可行资讯。该报告深入研究了不同地区和产品类型的消费者需求，包括治疗、诊断和益生菌。它还分析购买行为并确定关键客户群，例如医疗保健提供者、製药公司和个人消费者，使企业能够有效地制定策略。
  • 技术和监管发展：该报告进一步探讨了人类微生物组领域的最新技术进步，包括次世代定序、基于微生物组的药物开发和人工智慧诊断工具。它还探讨了主要政府政策、法规和政策以及资金筹措倡议的影响，例如与个人化医疗、临床试验和微生物组研究相关的政策、法规和政策以及资助措施的影响。这些见解将帮助相关人员了解不断变化的监管环境，并利用这个快速发展的市场中的成长机会。

报告中介绍的主要企业包括 Seres Therapeutics、Microbiome Therapeutics Innovation Group、Vedanta Biosciences Inc.、Metabiomics、Ferring Pharmaceuticals、Finch Therapeutics、BiomeBank、Biohm Technologies、Resbiotic、Immuron Limited 和 Maat Pharma。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测分析（包括国家在内的细分市场和地区）
  • 公司概况（策略、产品、财务资讯、主要趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔

第三章 商业景气

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 全球人类微生物组市场（按产品）

  • 介绍
  • 益生菌
  • 益生元
  • 补充
  • 其他的

6. 全球人类微生物组市场（按疾病）

  • 介绍
  • 糖尿病
  • 自体免疫疾病
  • 癌症
  • 肥胖
  • 其他的

7. 全球人类微生物组市场（依应用）

  • 介绍
  • 诊断
  • 治疗

8. 全球人类微生物组市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 泰国
    • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Seres Therapeutics
  • Microbiome Therapeutics Innovation Group
  • Vedanta Biosciences Inc.
  • Metabiomics
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • BiomeBank
  • Biohm Technologies
  • Resbiotic
  • Immuron Limited
  • Maat Pharma

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610813

The human microbiome market will grow at a CAGR of 20.42% to reach US$2,383.317 million in 2030 from US$941.215 million in 2025.

Major factors driving the global human microbiome market growth are increasing instances of lifestyle diseases, diarrheal infections, predominant changes in the lifestyle of the global population, and an increase in the aged population and its applications in healthcare. Moreover, technological enhancements in biomedical sciences and growing research investment in technology and product sectors is also positively impacting the market growth positively. However, lack of awareness about the use and advantages of prebiotics and probiotics and government restrictions on their usage are major challenges for the market players.

Market Trends:

  • In-depth analysis of the human microbiome market: The global human microbiome market report delivers a comprehensive examination of the industry landscape, providing strategic and executive-level insights backed by data-driven forecasts and detailed analysis. This report serves as a critical resource for understanding the market's current state and future trajectory, helping stakeholders make informed decisions.
  • Actionable insights for decision-makers: Regularly updated, the report equips decision-makers with actionable intelligence on prevailing market trends, emerging opportunities, and competitive dynamics. It offers a deep dive into consumer demand across various regions and product categories, including therapeutics, diagnostics, and probiotics. The report also analyzes purchasing behaviors and identifies key customer segments, such as healthcare providers, pharmaceutical companies, and individual consumers, enabling businesses to tailor their strategies effectively.
  • Exploration of technological and regulatory developments: The report further investigates the latest technological advancements in the human microbiome field, such as next-generation sequencing, microbiome-based drug development, and AI-driven diagnostic tools. It also examines the impact of key government policies, regulations, and funding initiatives, such as those related to personalized medicine, clinical trials, and microbiome research. These insights help stakeholders navigate the evolving regulatory landscape and capitalize on growth opportunities in this rapidly advancing market.

Some of the major players covered in this report include Seres Therapeutics, Microbiome Therapeutics Innovation Group, Vedanta Biosciences Inc., Metabiomics, Ferring Pharmaceuticals, Finch Therapeutics, BiomeBank, Biohm Technologies, Resbiotic, Immuron Limited, Maat Pharma among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Global Human Microbiome Market Segmentations:

Global Human Microbiome Market Segmentation by product:

  • The market analyzed by product into the following:
  • Probiotic
  • Prebiotics
  • Supplements
  • Others

Global Human Microbiome Market Segmentation by disease:

  • The market analyzed by disease into the following:
  • Diabetes
  • Autoimmune Disorder
  • Cancer
  • Obesity
  • Others

Global Human Microbiome Market Segmentation by application:

  • The market analyzed by application into the following:
  • Diagnostics
  • Therapeutics

Global Human Microbiome Market Segmentation by regions:

The study also analysed the global human microbiome market into the following regions, with country level forecasts and analysis as below:

  • North America (US, Canada and Mexico)
  • South America (Brazil, Argentina, and Others)
  • Europe (Germany, France, United Kingdom, Spain, Italy and Others
  • Middle East and Africa (Saudi Arabia, UAE and Others)
  • Asia Pacific (China, India, Japan, South Korea, Thailand and Others)

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Probiotics
  • 5.3. Prebiotics
  • 5.4. Supplements
  • 5.5. Others

6. GLOBAL HUMAN MICROBIOME MARKET BY DISEASE

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Autoimmune Disorder
  • 6.4. Cancer
  • 6.5. Obesity
  • 6.6. Others

7. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Therapeutics

8. GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Thailand
    • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Seres Therapeutics
  • 10.2. Microbiome Therapeutics Innovation Group
  • 10.3. Vedanta Biosciences Inc.
  • 10.4. Metabiomics
  • 10.5. Ferring Pharmaceuticals
  • 10.6. Finch Therapeutics
  • 10.7. BiomeBank
  • 10.8. Biohm Technologies
  • 10.9. Resbiotic
  • 10.10. Immuron Limited
  • 10.11. Maat Pharma

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations